Early chemo a ‘game-changer’ for metastatic prostate cancer

Early chemotherapy substantially boosts survival in metastatic hormone-sensitive prostate cancer, according the results of a US trial set to change clinical practice.

Until now, newly diagnosed prostate cancer patients have been treated with androgen deprivation therapy (ADT) alone, until resistance sets in, at which point they are offered chemotherapy.

But a randomised trial of 790